| Study | Reason for exclusion |
|---|---|
| Abciximab 2000 | Intravenous antiplatelet therapy |
| AbESTT 2005 | Intravenous antiplatelet therapy |
| AbESTT‐II/C 2008 | Intravenous antiplatelet therapy |
| AbESTT‐II/P 2008 | Intravenous antiplatelet therapy |
| AbESTT‐II/W 2008 | Intravenous antiplatelet therapy |
| Aoki 2000 | Not adequately randomised; participants allocated on alternating basis Not acute therapy |
| APLAUD 2000 | Not acute stroke therapy Randomisation up to 6 months post‐stroke |
| Apollonia 1989 | Not adequately randomised; confounded; people with acute and non‐acute stroke included |
| ARTIS 2012 | Intravenous antiplatelet therapy |
| Balkuv‐Ulutin 1989 | Not randomised |
| BRAVO 2000 | Not acute stroke therapy; people included up to 30 days post‐stroke Trial halted prematurely because of bleeding risk, but trial data remain unpublished |
| Chen 1988 | Not adequately randomised |
| Cheung 2000 | Intravenous antiplatelet therapy |
| CLEAR trial | Confounded trial |
| D'Andrea 1993 | No control group which did not receive antiplatelet therapy (picotamide versus aspirin versus aspirin and picotamide) |
| Fan 2003 | Ligustrazine, a kind of Chinese herbal medicine, is not an antiplatelet agent |
| FASTER 2007 | No control group (clopidogrel plus aspirin versus aspirin alone in minor stroke and TIA within 24 hours of onset) |
| Gao 1989 | No control group (aspirin versus ligustrazine versus betahistine) |
| Garcia Tigera 1994 | No control group (aspirin versus levamisol) |
| Hakim 1984 | Not randomised |
| Iida 1984 | Not acute stroke therapy |
| JASAP 2011 | No control group (extended‐release dipyridamole 200 mg plus acetylsalicylic acid 50 mg in a capsule, 2 capsules twice daily versus acetylsalicylic acid 81 mg,1 tablet once daily) Not acute stroke therapy; participants included between 1 week and 6 months after stroke |
| Joseph 1989 | Not adequately randomised |
| Junghans 2002 | Not randomised |
| Kamath 2001 | No results published, described as 'discontinued' |
| Kaye 1989 | No control group which did not receive antiplatelet therapy (aspirin and dipyridamole combined versus aspirin alone) |
| Lecrubier 1977 | Not acute stroke therapy |
| Li 1999 | Non‐randomised, dose escalation study |
| Li 2005 | Intravenous antiplatelet therapy |
| Liu 1994 | Method of allocation unclear, no relevant clinical outcomes reported |
| Matsumoto 2005 | Multiple antiplatelet agents |
| Monreal 1987 | No relevant clinical outcomes reported |
| Ohtomo 1991 | Intravenous antiplatelet therapy |
| SaTIS 2011 | Intravenous antiplatelet therapy |
| Seitz 2004 | No relevant clinical outcomes reported |
| Siebler 2003 | No relevant clinical outcomes reported |
| TACS 2000 | Not acute stroke therapy; participants included up to 6 months after stroke |
| TARDIS | Multiple antiplatelet agents. Ongoing trial |
| Wu 2005 | Ligustrazine, a kind of Chinese herbal medicine, is not an antiplatelet agent |
| Yan 1998 | Not adequately randomised |
| Zhang 2005 | Method of allocation unclear, no relevant clinical outcomes reported |
TIA: transient ischaemic attack